Arbor Pharmaceuticals Inc. is banking on safety advantages to differentiate Nymalize, an oral solution of the brain hemorrhage treatment nimodipine, from the generic gel capsule market.
FDA approved the Atlanta-based specialty pharma’s 505(b)(2) NDA May 10 for a new formulation, a 60 mg/20mL oral solution, of the calcium channel blocker nimodipine to improve neurological outcomes in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?